Ayala Pharmaceuticals, Inc.
ADXSAdvaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on agenetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL101 | Phase 2 | Adenoid Cystic Carcinoma | - | - |
Frequently asked questions
What is in Ayala Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Ayala Pharmaceuticals, Inc.'s (ADXS) pipeline across Phase 2. Its lead program is AL101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ayala Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ayala Pharmaceuticals, Inc. (ADXS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADXS biotech catalysts?→
Add ADXS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ayala Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.